Neurocrine Bio. (NBIX): KOL Expects Significant Uptake of Elagolix in Endometriosis, Tougher Sell in Uterine Fibroids - Jefferies

November 8, 2016 7:14 AM EST
Get Alerts NBIX Hot Sheet
Price: $41.30 -1.76%

Rating Summary:
    15 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 22 | Down: 34 | New: 34
Trade NBIX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst Biren Amin reiterated a Buy rating and $61 price target on Neurocrine Bio. (NASDAQ: NBIX) after hosting a dinner with an endometriosis and uterine fibroids (UF) specialist who shared his views on both markets, including where he sees GnRH antagonist treatment fitting relative to current and emerging treatments.

Amin commented, "In endometriosis, our expert expected significant uptake of elagolix as well as significant growth in the market. For UF, he thought the SPRMs would be in front of GnRH antagonists, but questioned whether tx cycles for SPRMs may hamper uptake."

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $44.13 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Jefferies & Co

Add Your Comment